Skip to main content

Table 1 Univariate and multivariate analysis of variables associated with incomplete cytoreduction at interval debulking surgery

From: A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience

  Total (93Pts.) R0 (65Pts.) Non-R0 (28 Pts.) Uni-variate p value Multi-variate p value
Age, years      
 Median (range) 60 (36–82) 59,5 (36–82) 65,7 (47–82) NS  
 Age ≥ 60 54 (58%) 32 (49,2%) 22 (78,6%) 0.011 0.007
FIGO stage      
 IIIA 9 (9,7%) 6 (9,2%) 3 (10,7%)   
 IIIB 14 (15%) 9 (13,8%) 5 (17,9%) NS  
 IIIC 58 (62,4%) 43 (66,2%) 15 (53,5%)   
 IV 12 (12,9%) 7 (10,8%) 5 (17,9%)   
Histology      
 High-grade serous 81(87%) 57 (87,6%) 24 (85,7%)   
 Endometroid 4 (4,3%) 2 (3,1%) 2(7,1%) NS  
 Mucinous 2 (2,2%) 1 (1,5%) 1 (3,6%)   
 Clear cell 2 (2,2%) 2 (3,1%) 0   
 Other/non specified 4 (4,3%) 3 (4,6%) 1 (3,6%)   
ECOG Performance Status      
 0 34 (37%) 26 (40%) 8 (29,6%) NS  
 1 44 (47,8%) 30 (46,2%) 14 (51,9%)   
 2 15 (15,2%) 9 (13,8%) 6 (21,4%)   
Ca 125 values, UI/dl      
 Median CA-125 at diagnosis (range) 2121 (10454–28) 1964 2793 NS NS
 CA-125 at diagnosis > 550 71 (76,3%) 46 (70,8%) 25 (89,3%) 0.044 0.014
 Median CA-125 post NACT (range) 342 (2620–7) 163 598 0.055 NS
 Ca 125 post NACT > 33 60 (65,9%) 35 (55,6%) 25 (89,3%) 0.002 NS
 CA 125 reduction post NACT < 96% 34 (38,2%) 26 (41,9%) 8 (29,6%) 0.034 NS
Chronic Disease Score (CDS)      
 1 61 (65,6%) 44 (67,7%) 17 (60,7%)   
 2 24 (25,8%) 17 (26,2%) 7 (25%) NS  
 3 8 (8,6%) 4 (6,2%) 4 (14,3%)   
Peritoneal Cancer Index      
 0–16 68 (73,1%) 58 (85,3%) 10 (35,8%) < 0.001 < 0.001
 > 16 25 (26,9%) 7 (10,7%) 18 (64,2%)
Chemotherapy regimen      
 - Carboplatin plus paclitaxel 81 (87,3%) 57 (87,6%) 24 (85,7%) NS  
 - Single agent carboplatin 3 (3,2%) 2 (3,1%) 1 (3,6%)
 - Carboplatin plus PLD 2(2,2%) 2 (3,1%) 0
 - Carboplatin plus paclitaxel plus bevacizumab 7 (7,6%) 4 (6,2%) 3 (10,7%)
  1. Pts patients, R0 complete cytoreduction, FIGO International Federation of Gynaecology and Obstretics, ECOG Eastern Cooperative Oncology Group, NACT neoadjuvant chemotherapy, PLD pegylated liposomal doxorubicin, NS not significant